“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,

Slides:



Advertisements
Similar presentations
TRIPs and Public Health: The Unresolved Debate Tenu Avafia tralac
Advertisements

Intellectual property rights and procurement = international developments & national experiences = Bi-regional Workshop on procurement and supply management.
Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.
Working world wide against HIV for the health and human rights of men who have sex with men Working world wide against HIV for the health and human rights.
J.P. Singh Georgetown University Communication, Culture, & Technology Program TRIPS: Negotiating Intellectual Property in the World Trading System J.
The Emergence of Anti-Counterfeiting Legislation in East Africa: Implications for Generic Supply and Treatment Access Mandeep Dhaliwal Tenu Avafia With.
Use of competition rules to address abuses of intellectual property rights CARRIBEAN REGIONAL WORKSHOP ON INTELLECTUAL PROPERTY AND ACCESS TO MEDICINES,
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.
CUTS INTERNATIONAL Assessing Policy based Competition Impediments in Pharmaceutical and Agriculture Product Marketing Sector in India 1 Swati Thapar, Research.
National symposium on Competition law: Evolution and Transition, 2012 Competition Policy for IP Issues Pradeep S Mehta Secretary General, CUTS International.
Overview of regional IP challenges and strategies for access to medicines in Africa: Case studies Egypt, Uganda and South Africa.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Challenges and Opportunities to Utilize TRIPS Flexibilities in Current Ukrainian Legislation: Potential Impact of IP Provisions in the Proposed EU FTA.
Economic Justifications for Open Access to Essential Drug Patents Sean Flynn Washington College of Law WIPIP 2007.
Can we create a global trade framework for health care R&D that puts patients first? James Love Consumer Project on Technology Washington, DC Presented.
The use of TRIPS flexibilities to protect health in South Africa and the opportunities for pro-public health reform of national legislation Nokhwezi Hoboyi.
Presentation to Civil Society meeting Lusaka 1 October 2013.
Presentation to Civil Society meeting Maseru 12 August 2014.
Assessing the impact of TRIPS-plus provisions on Public Healh: Lessons from Latin America David Vivas Eugui WTO Public Forum CSEND Roundtable.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
The TRIPs Amendment: Developments and implications Tralac/ Comomonwealth post Hong Kong Conference 10 April 2006 Tenu Avafia UNDP.
A very short introduction to patents & access to medicines.
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
 Critical Enablers for HIV, TB & Malaria Responses UNDP & Global Fund informal session 30 th meeting of the Global Fund Board Dr Mandeep Dhaliwal United.
Public health, innovation and intellectual property 1 |1 | Dr Germán Velásquez Director WHO Secretariat Public Health, Innovation and Intellectual Property.
Pharmaceutical Manufacturers Association PMA Status of National Production Capacity of Generic Medicines – Private Sector Perspective Emmanuel Mujuru,
The emergence of an Enforcement Agenda Intellectual Property Rights and Access to Essential Medicines: Challenges and Opportunities in Free Trade Agreement.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Action against AIDS, Germany: Dr. Christiane Fischer MD PHD (presenter )(BUKO Pharma-Kampagne), Astrid Berner Rodoreda (Bread for the World) Igor Oliynyk.
UNITAID The HIV/AIDS Medicines Patent Pool Initiative October 2010.
H I R S C H & P A R T N E R S A v o c a t S o l i c i t o r R e c h t s a n w a l t Pharmaceutical settlement agreements and competition law A litigation.
STRUCTURE AND FUNCTIONS OF COMPETITION AGENCIES. GENERAL STRUCTURE OF CA CAs differ in size, structure and complexity The structure depicts power distribution.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
What are the TRIPS flexibilities? How can their incorporation in patent legislation promote access to essential medicines? 25 November 2014, Maseru, Lesotho.
What are the TRIPS flexibilities? How will their incorporation in patent legislation promote access to essential medicines? IP and Access to Medicines:
Washington D.C., USA, July 2012www.aids2012.org Why do we need patent landscapes and what tools can be made available? Presenting the UNDP Patent.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
Can Competition-Promoting Policies Reduce Medicine Prices in Developing Countries? Loraine Hawkins ICIUM, Track 2c Economics Tuesday, 15 November,
The Pharma Sector: IP Rights and Competition Policy Ninette Dodoo Clifford Chance LLP UOHS Conference, 11 November 2009.
Washington D.C., USA, July 2012www.aids2012.org Methodology to Determine the Patent Status of Key ARVs and Other Essential Medicines: A Strategy.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN LESOTHO REPORT OF DAY 1 Botha Tiheli, Masello.
Presentation to Civil Society meeting Harare 21 January 2014.
PATENT POOL & its CONCERNS PATENT POOL & its CONCERNS Manmohan A Amonkar 20 July 2010.
Medicines and Related Substances Amendment Bill 2008 Presented by: Abeda Williams 5 August 2008 Pharmaceutical Industry Association of South Africa.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
A presentation by Moses Nkomo Intellectual Property Attorney and Consultant National Workshop on TRIPS and access to medicines in Zimbabwe Holiday Inn,
Law and Treatment Access AIDS Law Project briefing Portfolio Committee on Health Friday, 21 st February 2003 Jonathan Berger Law and Treatment Access Unit.
Sangmin Song, Director, Anti-Monopoly Div., KFTC MRFTA & IP Rights 1.
Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.
Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.
NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.
Prof. Frederick Abbott UNDP Consultant
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
Intellectual Property Protection and Access to Medicines
Access to Treatment: People Before Trade
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
LIDC Prague, 12 October 2012 EU competition law and end-of-lifecycle pharmaceutical products Blaž Višnar DG Competition DISCLAIMER “The views expressed.
The Price of Life A Legal Challenge to the Cost of Antiretroviral Therapies in South Africa Jonathan Berger Law & Treatment Access Unit AIDS Law Project.
Itumeleng Lesofe Competition Commission South Africa
Using competition policy to mitigate the impact of patent protection
LIDC Prague, 12 October 2012 EU competition law and end-of-lifecycle pharmaceutical products Blaž Višnar DG Competition DISCLAIMER “The views expressed.
Law and Treatment Access
Dr. Tenu Avafia HIV, Health and Development Group UNDP
Presentation transcript:

“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne, Australia Mandeep Dhaliwal, Tenu Avafia & Catherine Kirk HIV, Health and Development Group, UNDP

Global Commission on HIV and the Law Broad range of issues on HIV and law Bad laws & practices hinder effective AIDS responses e.g. TRIPS plus, anti-counterfeiting law Good laws exist and must be replicated 6 key recommendations on IP and treatment access Countries must proactively use other areas of law and policy such as competition law, price control policy and procurement law which can help increase access to pharmaceutical products

UNDP guide on competition law Covers – Competition law under international law – Anticompetitive behaviors and remedies – Market dominance and market definition – Challenges facing developing countries Includes – Model provisions principles for inclusion in national legislation being developed – Country case study examples

Sample of anti-competitive practices in the pharmaceutical sector Patent thickets to extend monopolies (1300 patents and applications in EU for individual medicine) Excessive or spurious litigation at the Patent Office or Health Agency Restrictive licensing practices – Exclusive grant-back clauses in licensing agreements – Pay for delay Abuse of dominance – Excessive/predatory pricing – Denying a competitor access to an essential facility – Exclusionary act Market collusion – Carving up markets – Price fixing Merging/acquiring generic competitors in large MICs India, Brazil, Egypt others

Advantages and challenges of using competition law to increase treatment Advantages Less multilateral regulation with competition policy More flexibility in TRIPS than patent laws Broader range of interested parties can use competition law – Civil society/Patient groups – NGOs – Generic companies Requirements/challenges Under-utilized flexibility, insufficient information on using competition law Can require complex enabling legislation and regulations Capacity constraints at competition authorities National level policy coherence Developing countries more susceptible to market concentration

Using competition law to increase treatment in South Africa Section 49 of the Competition Act of South Africa’s allows “any person” to submit a complaint to commission People living with HIV lodged a complaint against GSK and BI for excessive pricing of select ARVs, leading to the premature deaths – Hazel Tau and Others v GlaxoSmithKline and Boehringer Ingelheim Competition Commission found anticompetitive behaviour present. On grounds: – excessive pricing, and – denying competitor access to an essential facility Out of court settlements with the companies resulted in reduced royalties (from 30 % to 5%)

More examples from South Africa 2005: Competition law was again used by TAC against BMS differential pricing on Fungizone. – Result: 90 per cent price reduction 2007: Complaint by TAC and AIDS Law Project of excessive pricing on Efavirenz – Eventually, granted royalty-free licenses for efavirenz to 6 South African generic manufacturers.

Conclusion Access to health technologies is a fundamental human right. Competition remains underutilized public health TRIPS flexibility Cut and paste model from developed to developing countries not recommended Policy coherence is essential between competition, patent, drug regulatory, procurement officials to build stronger competition frameworks. Competition law should form part of the toolkit used by countries in developing sustainable treatment policy responses.

THANK YOU Mandeep Dhaliwal United Nations Development Programme